Five-Year Assessment of Time of Sputum Smears Conversion and Outcome and Risk Factors of Tuberculosis Patients in Central Iran

Table 3

Impact of comorbidities and demographic, microbiological, and therapeutic variables on outcome of patients ().

	Outcome
Characteristic		Favorable	Unfavorable			value
		Cure	Failure	Death	Transfer-out
Sex	Male	83 (72.8)	6 (5.3)	11 (9.6)	14 (12.3)	0.027
	Female	84 (86.6)	3 (3.1)	8 (8.2)	2 (2.1)
Age	≤50	65 (75.7)	2 (2.3)	4 (4.6)	15 (17.4)	0.000
	>50	102 (81.6)	7 (5.6)	15 (12)	1 (0.8)
Nationality	Iranian	88 (80)	6 (5.5)	10 (9.1)	6 (5.5)	0.858
	Non-Iranian	79 (79)	3 (3)	9 (9)	9 (9)
Initial sputum grading	≤2+	128 (81)	3 (1.9)	15 (9.5)	12 (7.6)	0.398
	3+	39 (75)	6 (11.5)	4 (7.7)	3 (5.8)
Accompanying disease	DM	15 (75)	5 (25)	0 (0)	0 (0)	0.000
	Other comorbidities	10 (58.8)	0 (0)	6 (35.3)	1 (5.9)
	No comorbidity	142 (81.6)	4 (2.3)	13 (7.5)	15 (8.6)
Treatment regimen	HRZE	147 (80)	8 (4.3)	17 (9.2)	12 (6.5)	0.881
	HRZES^*	13 (72.2)	1 (5.6)	1 (5.6)	3 (16.7)
	HRE	59 (83.3)	0 (0)	1 (1.67)	0 (0)
	HZE	2 (100)	0 (0)	0 (0)	0 (0)
Treatment category	CAT I	153 (80.5)	8 (4.2)	17 (8.9)	12 (6.3)	0.53
	CAT II	14 (70)	1 (5)	2 (10)	3 (15)
Sputum conversion	2 m for CAT I, 3 m for CAT II	146 (92.4)	2 (1.26)	4 (2.5)	6 (3.8)	0.000
	>2 m and >3	21 (67.8)	7 (28.6)	2 (6.4)	1 (3.2)

 ^*Isoniazide, rifampicin, pyrazinamide, ethambutol, and streptomycin.